Mayo Clinic Laboratory and pathology research roundup: October 12

By Chantell Canfield • October 12, 2021

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial.

Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. Via PubMed

Read more.

Published to PubMed This Week

• Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients: A randomized clinical trial.
  JAMA
• Membranous nephropathy.
  Nature Reviews
• Diagnosis and classification of ileal pouch disorders: consensus guidelines from the international ileal pouch consortium.
  Lancet Gastroenterol Hepatology
• USP37 regulates DNA damage response through stabilizing and deubiquitinating BLM.
  Nucleic Acids Research
• SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
  Nature Communications
• Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
  Clinical Cancer Research
• Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
  Neuro Oncology
• HLA antibody rates are not increased in a regional group of male COVID-19 convalescent plasma donors.
  Clinical Infectious Disease
• NSAID-induced colopathy.
  Mayo Clinic Proceedings
• Renal Neoplasia in Hyperparathyroidism-Jaw tumor syndrome.
  Mayo Clinic Proceedings

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.